Welcome to our dedicated page for Gain Therapeutics SEC filings (Ticker: GANX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Gain Therapeutics, Inc. (GANX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, clinical-stage biotechnology company and an emerging growth company, Gain Therapeutics uses SEC reports to provide detailed information on its business, financial condition and progress in developing allosteric small molecule therapies such as GT-02287 for Parkinson’s disease.
Through this page, readers can access annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically describe the company’s operations, risk factors, research and development activities, and financial statements. Current reports on Form 8-K capture material events, including clinical data updates from the Phase 1b study of GT-02287, financial results, changes in corporate governance, amendments to the certificate of incorporation, and other significant corporate actions.
Investors interested in capital structure and corporate actions can review filings that discuss increases in authorized shares of common stock, shareholder meeting results, and other matters submitted to a vote of security holders. These documents help explain how Gain Therapeutics manages its equity base as it advances its clinical and preclinical programs.
For those tracking clinical development disclosures, 8-K filings and related exhibits often summarize preliminary safety and tolerability findings, exploratory biomarker endpoints such as glucosylsphingosine (GluSph) changes in cerebrospinal fluid, and recommendations from independent data monitoring committees. These filings complement the company’s press releases by providing formal regulatory context for key milestones in the GT-02287 program.
Stock Titan enhances access to these documents with AI-powered summaries that highlight important points from lengthy filings, helping readers interpret complex sections without replacing the original text. Real-time updates from the EDGAR system ensure that new 10-K, 10-Q, 8-K and other forms are available as they are filed, while tools for viewing insider-related filings such as Form 4, when present, can assist in monitoring transactions by directors and officers of Gain Therapeutics.
Gain Therapeutics, Inc. reported that CEO and President Gene Mack received a grant of 200,000 employee stock options to buy common stock at an exercise price of $1.86 per share. All 200,000 options were newly awarded and represent his total option holdings reported after this grant.
The options expire on March 24, 2036. According to the vesting terms, 25% of the underlying shares vest on March 24, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, as long as he continues in service through each vesting date.
Gain Therapeutics, Inc. reported that officer Gianluca Fuggetta received a grant of employee stock options covering 50,000 shares of common stock. The options have an exercise price of $1.86 per share and expire on March 24, 2036.
These options were awarded as a compensation-related grant, not an open-market purchase. According to the vesting terms, 25% of the underlying shares vest on March 24, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, as long as he remains in continuous service. Following this grant, he holds 50,000 options directly.
Gain Therapeutics files its annual report describing a CNS-focused biotech developing small-molecule drugs that correct protein misfolding using its Magellan computational discovery platform. The lead candidate, GT-02287, targets GCase for Parkinson’s disease, Gaucher disease and other neurodegenerative conditions.
A 72-subject Phase 1 trial in healthy volunteers showed GT-02287 was generally well tolerated with linear pharmacokinetics, CNS exposure and 53% higher GCase activity at the highest 13.5 mg/kg dose. A 90-day Phase 1b trial in 21 Parkinson’s patients completed Part 1 with 19 completers and a 9‑month extension under way, with Phase 2 planned for the second half of 2026. Gain reports exclusive Magellan-related licenses from Minoryx, global composition-of-matter patents for GBA and GLB programs expected to run to 2037, and 42,241,947 common shares outstanding as of February 28, 2026.
Gain Therapeutics reported its fourth quarter and full-year 2025 results and provided a corporate update centered on its lead Parkinson’s disease candidate GT-02287. The company highlighted encouraging Phase 1b data, including central nervous system target engagement and stable or improved MDS-UPDRS scores after 150 days of treatment.
For the year ended December 31, 2025, research and development expenses were $10.2 million, down from $10.8 million in 2024, mainly from pipeline cost optimization. General and administrative expenses fell to $8.5 million from $9.6 million, primarily due to lower stock-based compensation and legal fees.
Net loss for 2025 was $20.2 million, or $0.61 per share, compared with a $20.4 million loss, or $0.89 per share, in 2024. Cash, cash equivalents and marketable securities increased to $20.8 million as of December 31, 2025, up from $10.4 million a year earlier, providing additional funding runway for ongoing clinical development.
Gain Therapeutics, Inc. reported new clinical and biomarker data from its Phase 1b study of GT-02287 in Parkinson’s disease, presented at the AD/PD 2026 conference. In Part 1, 19 participants completed dosing and 16 chose to enter a nine‑month extension, and an independent Data Monitoring Committee recommended the study continue unchanged.
In participants with elevated baseline glucosylsphingosine (GluSph) in cerebrospinal fluid, GluSph fell substantially after 90 days of GT-02287 and DOPA decarboxylase levels also declined. After 150 days, MDS‑UPDRS scores remained stable overall, with a 6.7‑point difference in combined Part II and III scores favoring those with high baseline GluSph. The company also highlighted a novel GCase modulator series led by GT‑04686 that is orally available, brain‑penetrant and ready for IND‑enabling studies in Parkinson’s and other neurological disorders.
Gain Therapeutics, Inc. filed a current report to state that it has posted an investor presentation on its website. On February 3, 2026, the company furnished a set of business overview slides as Exhibit 99.1. These slides are meant to describe the company’s business and are being provided to the SEC for informational purposes only.
The materials are expressly described as “furnished” rather than “filed,” meaning they are not subject to certain liability provisions of the Exchange Act and are not automatically incorporated into other securities law filings unless specifically referenced.
Gain Therapeutics reported new exploratory data from its Phase 1b study of GT-02287 in people with Parkinson’s disease. All participants who started with elevated levels of glucosylsphingosine (GluSph) in cerebrospinal fluid showed large decreases back toward levels seen in healthy individuals after 90 days of treatment, meeting a prespecified exploratory endpoint.
The Phase 1b trial enrolled 21 participants, with 19 completing the 90-day dosing period and 15 (79%) choosing to enter a nine‑month extension expected to conclude in September 2026. GT-02287 has been generally well-tolerated over 90 days at plasma exposures within the projected therapeutic range, and the data monitoring committee recommended the study continue with no changes.
Earlier Phase 1 data in healthy volunteers showed favorable safety, central nervous system exposure in the projected therapeutic range, and increased glucocerebrosidase (GCase) activity at clinically relevant doses. Gain Therapeutics stated it has sufficient capital to fund operations through completion of the Phase 1b extension and through year-end 2026.
Gain Therapeutics (GANX) reported Q3 2025 results showing continued investment in R&D and an increased net loss. Net loss was $5.28 million (vs. $4.49 million a year ago), or $(0.15) per share. Operating expenses were $4.79 million. For the first nine months, net loss totaled $15.62 million.
Cash and cash equivalents were $8.81 million at September 30, 2025. The company disclosed that this balance will not fund operations for 12 months from issuance; management stated substantial doubt about continuing as a going concern and plans to seek additional financing and reduce costs to extend runway beyond the first quarter of 2026.
To bolster liquidity year-to-date, GANX raised capital via an ATM program ($4.91 million net) and a July 2025 public offering of 4,501,640 shares and warrants (gross $7.0 million, $6.0 million net), plus an over-allotment of 675,246 shares and additional warrants (gross $1.1 million, $1.0 million net). Cash used in operating activities for the nine months was $13.85 million. Shares outstanding were 35,976,390 as of September 30, 2025; as context, 36,097,536 were outstanding as of October 31, 2025.
Gain Therapeutics, Inc. filed a current report to furnish a press release announcing its financial results for the third quarter ended September 30, 2025, along with a business update. The press release, dated November 12, 2025, is included as Exhibit 99.1. The company states that this information is being furnished under the rules governing current reports and is not considered filed for liability purposes or automatically incorporated into other securities law filings unless specifically referenced.
Gain Therapeutics, Inc. filed Amendment No. 1 to a mixed shelf registration (Form S-3) to register up to $100,000,000 of securities, including common stock, preferred stock, warrants, debt securities, subscription rights, and units, which may be offered and sold from time to time.
The company may sell securities directly, through agents, dealers, or underwriters, and may use market-based methods such as at-the-market offerings, with terms set in future prospectus supplements. Net proceeds, if and when securities are sold, are expected to be used for working capital and general corporate purposes.
GANX is listed on Nasdaq (symbol “GANX”); the last reported sale price was $1.90 per share on November 6, 2025. As of November 3, 2025, 36,241,000 shares of common stock were outstanding; this figure provides baseline context and is separate from the shelf registration capacity.